Monteverde & Associates Investigates Proposed Sales of Multiple Companies

Shareholders of ICVX, EAR, CVLY, IMGN could see significant changes in the wake of proposed sales.

Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC, is investigating multiple proposed company sales.
Icosavax, Inc. is proposed to be sold to AstraZeneca, with ICVX shareholders expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share.
Eargo, Inc. is proposed to be sold to an affiliate of Patient Square Capital, with EAR shareholders expected to receive $2.55 in cash per share.
Codorus Valley Bancorp, Inc. is proposed to be sold to Orrstown Financial Services, Inc., with CVLY shareholders expected to own approximately 44% of the outstanding shares of the combined company.
ImmunoGen, Inc. is proposed to be sold to AbbVie Inc., with IMGN shareholders expected to receive $31.26 in cash per share.